

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2014/075394 A1

(43) International Publication Date
22 May 2014 (22.05.2014)

- (51) **International Patent Classification:**
C07F 1/12 (2006.01) *G01N 31/22* (2006.01)
A61K 31/28 (2006.01) *G01N 21/77* (2006.01)
A61P 35/00 (2006.01)
- (21) **International Application Number:**
PCT/CN2013/001397
- (22) **International Filing Date:**
15 November 2013 (15.11.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/728,039 19 November 2012 (19.11.2012) US
- (71) **Applicant:** THE UNIVERSITY OF HONG KONG
[CN/CN]; Pokfulam Road, Hong Kong (CN).
- (72) **Inventors:** CHE, Chiming; Flat 5, 5th Floor, Block A,
Parkway Court, 4 Park Road, Hong Kong (CN). ZOU,
Taotao; No.25B, 13th Floor, Kwan Yick Building, Phase
1, 430-440 Des Voeus Road West, Sheung Wan, Hong
Kong (CN).
- (74) **Agent:** CHINA PATENT AGENT (HK)LTD.; 22/F.,
Great Eagle Center, 23 Harbour Road, Wanchai, Hong
Kong (CN).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.
- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report (Art. 21(3))

(54) **Title:** NOVEL GOLD(III) COMPLEXES CONTAINING N-HETEROCYCLIC CARBENE LIGAND, SYNTHESIS, AND THEIR APPLICATIONS IN CANCER TREATMENT AND THIOL DETECTION

(57) **Abstract:** Provided herein is a method of synthesis of Au(III)-NHC complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Au(III)-NHC complexes. Also provided is method of detecting thiol in a biological system. The Au(III)-NHC complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.



WO 2014/075394 A1

**NOVEL GOLD(III) COMPLEXES CONTAINING N-HETEROCYCLIC
CARBENE LIGAND, SYNTHESIS, AND THEIR APPLICATIONS IN
CANCER TREATMENT AND THIOL DETECTION**

Related Applications

[0001] This application claims the benefit of U.S. provisional application serial number: 61/728,039, filed November 19, 2012, which is hereby incorporated by reference in its entirety.

1. Introduction

[0002] Described herein are gold(III) complexes containing N-heterocyclic carbene ligand, a method of synthesis of the gold(III) complexes containing N-heterocyclic carbene ligand, methods of treating and preventing cancer or tumor using the gold(III) complexes containing N-heterocyclic carbene ligand and a method of detecting thiols using the gold(III) complexes containing N-heterocyclic carbene ligand. Also described are therapeutic and prophylactic compositions containing a purified gold(III) complexes containing N-heterocyclic carbene ligand. In certain embodiments, the methods of treating and preventing cancer or tumor are in combination with other cancer or tumor treatment. In certain embodiments, the cancer or tumor treatment is chemotherapy, radiation therapy, gene therapy, surgery or a combination thereof.

2. Background

[0003] As stimulated by the clinical success of *cis*-diamminedichloroplatinum (cisplatin), a platinum(II) complex, for the treatment of cancers, scientists have paid great attention to the development of metal-based anticancer drugs which target DNA including the cisplatin analogues and some ruthenium(II)-arene complexes [Sadler, P. J. et al. *Curr. Opin. Chem. Biol.* **2008**, *12*, 197]. However, severe side effects and the induced drug resistance are commonly encountered and thus subsequently have hampered the wider applications of these DNA binding agents. Recently, some metal complexes including gold(III)-porphyrin [Che, C.-M. et al. *Chem. Commun.* **2011**, *47*,

9554-9560, Che C.-M. et al. *Chem. Commun.* **2003**, 1718-1719.], gold(I)-NHC [J. Berners-Price, S. J., Filipovska A. et al, *J. Am. Chem. Soc.* **2008**, *130*, 12570-12571] and gold(III) dithiocarbamate [Fregona, D. et al. *J. Med. Chem.* **2006**, *49*, 1648-1657.] complexes were found to target specific proteins or enzymes, and were capable of overcoming some of the drawbacks of the DNA binding agents by virtue of their different anticancer mechanisms. Despite that numerous previously reported gold(III) complexes like, $[\text{Au}(\text{bipy})(\text{OH})_2]^+$ (bipy= 2,2'-bipyridine), [Messori, L. et al. *Coord. Chem. Rev.* **2009**, *253*, 1692-1707] showed satisfied antiproliferative ability, examples on *in vivo* tumor inhibition are sparse.

[0004] Fluorescent thiol-sensitive probes have spurred increasing interests especially in biological area, as the cellular thiol level is linked with a great many diseases like cancer, AIDS (Acquired immune deficiency syndrome) and so forth [Yoon, J., *Chem. Soc. Rev.* **2010**, *39*, 2120-2135; Herzenberg, L. A. et al. *Proc. Natl. Acad. Sci. U. S. A.* **1997**, *94*, 1967-1972]. Soft metals and metals with tunable redox potentials should be a good starting point to design thiol probes. Gold(III) complexes are always unstable under physiological conditions and will be reduced to Au(I) or even Au(0) by physiological thiols. As Au(III) is usually 4-coordinated but Au(I) is usually 2-coordinated, reduction of Au(III) to Au(I) is accompanied by the release of coordinated ligand(s). If the ligand is highly fluorescent, intraligand emission would be quenched due to the presence of low energy Au(III) $5d_{x^2-y^2}$ orbital. Upon reduction of Au(III) to Au(I) by thiols, the fluorescent ligand(s) will be released and switch on the emission.

[0005] While the anti-cancer properties of many gold complexes including that of Au(III) and Au(I) are attributed to Au(I), Au(I) ion is unstable under physiological conditions [Sadler, P. J. et al. *Met.-Based Drugs* 1994, *1*, 107-144]. The present inventors discovered that N-heterocyclic carbene (NHC) ligand(s) is able to stabilize Au(I) against reduction to Au(0) and/or demetalation under physiological conditions.


[0006] As 2,6-bis(1*H*-benzo[*d*]imidazol-2-yl)pyridine (H₂BPB) and its analogue 2,6-di(1*H*-imidazol-2-yl)pyridine (H₂IPI) and 2,6-di(1*H*-pyrazol-5-yl)pyridine (H₂PPP) are highly emissive and also widely used in biological systems [Che, C.-M. et al. *Chem. Eur. J.* **2010**, *16*, 6900-6911], the present inventors employ the scaffold to develop novel gold(III) complexes.

[0007] Thus, the gold(III) complexes containing multi-dentate N[^]N[^]N ligand and NHC moiety provide dual anti-cancer and fluorescent switch-on properties.

3. Summary

[0008] Described herein is a method of synthesis of novel Au(III)-NHC complexes, a composition comprising Au(III)-NHC complexes and methods of using the Au(III)-NHC complexes in cancer/tumor treatment and prevention and a method of detecting thiol. In one embodiment, the method of treatment and prevention is in combination with one or more cancer/tumor therapies.

[0009] In one embodiment, a method to synthesize cyclometalated N[^]N[^]N-Au-Cl, where N[^]N[^]N refers to deprotonated 2,6-bis(1*H*-benzo[*d*]imidazol-2-yl)pyridine (BPB), 2,6-di(1*H*-imidazol-2-yl)pyridine (IPI), or 2,6-di(1*H*-pyrazol-5-yl)pyridine (PPP), and N[^]N[^]N-Au-NHC contains two steps:



[0010] wherein,

[0011] R₁, R₂, R₇, R₈, are each independently selected from the group -H, and R₃, R₄, R₁₀, R₁₁ are each dependently selected from an electron pair or -H; or each pair of

R₁ and R₃, R₂ and R₄, R₇ and R₈, R₁ and R₁₀, R₂ and R₁₁ is independently joined together to form



;

[0012] R₅, R₆, R₉, are each independently selected from a -H, -CH₃, -C₄H₉, -C₆H₁₃, -C₈H₁₇, -C₁₀H₂₁, -C₁₆H₃₃, -C₃H₆PPh₃⁺;

[0013] Base refers to an alkali; non-limiting examples of an alkali include NaOAc, NaOH, KOAc, Na₂CO₃;

[0014] n is an integer ranging from +1 to +2;

[0015] y is equal to the absolute value of n/b; and


[0016] X is selected from a carbon or a nitrogen atom;

[0017] Y is selected from a carbon or a nitrogen atom;

[0018] AgZ is a soluble silver(I) salt, non-limiting examples of a silver(I) salt include silver triflate, silver nitrate, silver hexafluorophosphate;

[0019] W is selected from Br, I, or Cl.

[0020] In another embodiment, provided herein is a method for cancer or tumor treatment and prevention resulting in induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase or inhibition of *in vivo* tumor growth. In one embodiment, provided herein is a method comprising administering to a subject in need thereof a composition comprising an effective amount of a Au(III)-NHC complex. In one embodiment, the Au(III)-NHC complex is a gold(III) complex described herein represented by the structural formulae of **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,



I

[0021] R_1, R_2, R_7, R_8 , are each independently selected from the group $-H$, and R_3, R_4, R_{10}, R_{11} are each dependently selected from an electron pair or $-H$; or each pair of R_1 and R_3, R_2 and R_4, R_7 and R_8, R_1 and R_{10}, R_2 and R_{11} is independently joined together to form



;

[0022] R_5, R_6, R_9 , are each independently selected from a $-H, -CH_3, -C_4H_9, -C_6H_{13}, -C_8H_{17}, -C_{10}H_{21}, -C_{16}H_{33}, -C_3H_6PPh_3^+$;


[0023] n is an integer ranging from +1 to +2;

[0024] y is equal to the absolute value of n/b ; and

[0025] X is selected from a carbon or a nitrogen atom;

[0026] Y is selected from a carbon or a nitrogen atom;

[0027] In another embodiment, provided herein is a method for detecting thiol-containing compounds, such as, but not limited to, cysteine (Cys), glutathione (GSH), dithiothreitol (DTT), comprise an effective amount of the Au(III)-NHC complexes, depending on the fluorescence changes at proper wavelength. The Au(III)-NHC complex is a gold(III) complex described herein can be represented by the structural formula of I, or an acceptable salt thereof, wherein,



I

[0028] R_1, R_2, R_7, R_8 , are each independently selected from the group $-H$, and R_3, R_4, R_{10}, R_{11} are each dependently selected from an electron pair or $-H$; or each pair of R_1 and R_3, R_2 and R_4, R_7 and R_8, R_1 and R_{10}, R_2 and R_{11} is independently joined together to form



;

[0029] R_5, R_6, R_9 , are each independently selected from a $-H, -CH_3, -C_4H_9, -C_6H_{13}, -C_8H_{17}, -C_{10}H_{21}, -C_{16}H_{33}, -C_3H_6PPh_3^+$;

[0030] n is an integer ranging from +1 to +2;

[0031] y is equal to the absolute value of n/b ; and

[0032] X is selected from a carbon or a nitrogen atom;

[0033] Y is selected from a carbon or a nitrogen atom.

[0034] The Au(III)-NHC complexes are stable in air and aqueous solutions like phosphate-buffered saline (PBS) conditions. They are very sensitive to physiological thiols and can be reduced to generate the anti-cancer active Au(I)-NHC complexes which are relatively inert to excel thiols, and the reduction process is also accompanied with the release of highly fluorescent ligand. The Au(III)-NHC complexes display similar anti-cancer or anti-tumor activity to the clinically used cisplatin and can inhibit the tumor growth of mice bearing HeLa xenograft. The release of the fluorescent ligand upon Au(III) to Au(I) reduction in the presence of thiols leads them to be excellent bio-probes to detect physiological thiols. In addition,

the ease of syntheses (2 steps) and structural modification also helps these complexes for prevalent biological applications.

4. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] FIGS. 1 (A) and (B) show Chemical structures of the Au(III)-NHC complexes.

[0036] FIGS. 2(A) and (B) show Crystal structure of 1 (A) and 9 (B)

[0037] FIGS. 3(A)-(C) show A) ESI-MS analysis of the mixture of 1 and GSH. B) ¹H NMR spectra (400 MHz) of free GSH (top), a mixture of GSH and 2 in a 7:1 molar ratio after mixing for 10 min (middle), and 2 (bottom); intensity ratios are shown. (C) Proposed reaction of the Au(III)-NHC complexes with GSH under physiological like conditions.


[0038] FIGS. 4(A)-(C) show A) Cell based TrxR activity for 1(IPI-Au-NHC(2Me)), 2 (IPI-Au-NHC(Me,C4)) and 9 (BPB-Au-NHC(2Me)) after treating for 1 h. B) Western blotting results of 9 towards PARP, caspase 9, caspase 7, caspase 3. C) Proposed anticancer pathway

[0039] FIGS. 5(A)-(D) show *In vivo* tumor inhibition effect : A). Graphic representation of tumor volume changes after treating mice bearing HeLa xenograft with 3 mg/kg of 5 or solvent; B) Body weight changes after treating mice bearing HeLa xenograft with 3 mg/kg of 5 or solvent; C) & D) Photos of mouse tumors in different groups.

[0040] FIGS. 6(A)-(C) show A) Fluorescence intensity before (red) and after (blue) adding GSH or Cys (2 mM) into 20 μM of 9 in PBS:DMSO=9:1(v/v). B) Fluorescence response of 9 towards different analysts. C) Fluorescence microscopy images of HeLa cells after treating with 20 μM of 9 for 10 min.


5. DETAILED DESCRIPTION

[0041] Disclosed are the synthesis of novel gold(III) [or Au(III) or Au³⁺] complexes containing N-heterocyclic carbene ligand (NHC), novel gold(III) [or Au(III) or Au³⁺] complexes containing N-heterocyclic carbene ligand (NHC), composition comprising novel gold(III) [or Au(III) or Au³⁺] complexes containing N-heterocyclic carbene ligand (NHC), methods of treating and preventing cancer or tumor in a subject, and a method of detecting thiol. Disclosed herein is a method of treating or preventing cancer/tumor comprising administering a pharmaceutical composition comprising at least one of the Au(III)-NHC complexes in an effective amount for anti-cancer or anti-tumor activity. In certain embodiments, anti-cancer or anti-tumor activities includes, but are not limited to, the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and inhibition of *in vivo* tumor growth. Provided herein is a method of detecting thiol which comprises detecting thiol containing compounds using at least one of the Au(III)-NHC complexes. In an embodiment, a signal is detected depending on fluorescence changes at proper wavelength. As provided herein, in one embodiment, Au(III)-NHC complexes refer to a molecule of a gold(III) ion connected to a tridentate ligand and N-heterocyclic carbene ligand. In one embodiment, gold(III) [or Au(III) or Au³⁺] complexes containing N-heterocyclic carbene ligand (NHC) is represented by structural formula I, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.



I

[0042] R_1, R_2, R_7, R_8 , are each independently selected from the group $-H$, and R_3, R_4, R_{10}, R_{11} are each dependently selected from an electron pair or $-H$; or each pair of R_1 and R_3, R_2 and R_4, R_7 and R_8, R_1 and R_{10}, R_2 and R_{11} is independently joined together to form



[0043] R_5, R_6, R_9 , are each independently selected from a $-H, -CH_3, -C_4H_9, -C_6H_{13}, -C_8H_{17}, -C_{10}H_{21}, -C_{16}H_{33}, -C_3H_6PPh_3^+$;




[0044] n is an integer ranging from +1 to +2;

[0045] y is equal to the absolute value of n/b ; and


[0046] X is selected from a carbon or a nitrogen atom;

[0047] Y is selected from a carbon or a nitrogen atom;

[0048] As used herein, the term "tridentate ligand" refers to a di-anionic substituted/non-substituted 2,6-bis(1*H*-benzo[*d*]imidazol-2-yl)pyridine (H_2BPB) and its analogue 2,6-di(1*H*-imidazol-2-yl)pyridine (H_2IPI), 2,6-di(1*H*-pyrazol-5-yl)pyridine (H_2PPP) ligand. Non-limiting examples of the deprotonated $N^{\wedge}N^{\wedge}N$ ligands are:



[0049] As used herein, the term "N-heterocyclic carbene" refers to a ligand having one of the following chemical structures:



[0050] Wherein R₅, R₆ are each independently selected from a -CH₃, -C₄H₉, -C₆H₁₃, -C₈H₁₇, -C₁₀H₂₁, -C₁₆H₃₃, -C₃H₆PPh₃⁺

[0051] R₇, R₈ are each independently selected from the group consisting of -H; or the pair R₇, R₈ is joined together to form



[0052] It will be understood that the di-anionic N⁻N⁻N ligand can form a non-neutral complex with the gold(III) ion. For instance, the net positive charge on the gold(III) can be greater than the absolute net negative charge of the N⁻N⁻N ligand. In view of this, there can be at least one counter-anion coordinated to the Au(III)-NHC complex for charge neutralization.

[0053] Accordingly, the phrase "acceptable salt," as used herein, includes salts formed from the charged Au(III)-NHC complex and counter-anion(s).

[0054] As used herein, the phrase "counter-anion" refers to an ion associated with a positively charged Au(III)-NHC complex. Non-limiting examples of counter-ions include halogens such as fluoride (F⁻), chloride (Cl⁻), bromide (Br⁻), iodide (I⁻); sulfate (SO₄²⁻); phosphate (PO₄³⁻); trifluoromethanesulfonate (triflate, ⁻OTf or CF₃SO₃⁻); acetate (⁻OAc); nitrate (NO₃⁻); perchlorate (ClO₄⁻); hexafluorophosphate (PF₆⁻) and hexafluoroacetylacetonate ([CF₃C(O)CHC(O)CF₃]⁻).

[0055] In one embodiment, the invention relates to the synthesis of novel gold(III) [or Au(III) or Au³⁺] bearing N-heterocyclic carbene ligand.


[0056] In another embodiment, the invention relates to a pharmaceutical composition for cancer treatment by inhibition of the proliferation of cancer cells *in vitro* comprising an effective amount of one or more of the Au(III)-NHC complexes.

[0057] In another embodiment, the invention relates to a pharmaceutical for cancer treatment by inhibition or poisoning of thioredoxin reductase comprising an effective amount of one or more of the Au(III)-NHC complexes.

[0058] In another embodiment, the invention relates to a pharmaceutical composition for cancer treatment by the inhibition of tumor growth *in vivo* comprising an effective amount of one or more of the Au(III)-NHC complexes.

[0059] In another embodiment, the invention relates to fluorescent detecting thiol-containing compounds such as cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), and the application in cellular thiol imaging, comprising an effective amount of a Au(III)-NHC complex.

[0060] The Au(III)-NHC complexes of this invention can be represented by one or more of structural formula I, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.



I

[0061] R₁, R₂, R₇, R₈, are each independently selected from the group –H, and R₃, R₄, R₁₀, R₁₁ are each dependently selected from an electron pair or –H; or each pair of

R₁ and R₃, R₂ and R₄, R₇ and R₈, R₁ and R₁₀, R₂ and R₁₁ is independently joined together to form



;

[0062] R₅, R₆, R₉, are each independently selected from a -H, -CH₃, -C₄H₉, -C₆H₁₃, -C₈H₁₇, -C₁₀H₂₁, -C₁₆H₃₃, -C₃H₆PPh₃⁺;

[0063] n is an integer ranging from +1 to +2;

[0064] y is equal to the absolute value of n/b; and

[0065] X is selected from a carbon or a nitrogen atom;

[0066] Y is selected from a carbon or a nitrogen atom.

[0067] In one embodiment, the invention relates to a pharmaceutical composition for treating or preventing cancer/tumor. In certain embodiments, the treatment and prevention comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In one embodiment, the method comprises administering an effective amount of the Au(III)-NHC complexes to a subject. In one embodiment, the method comprises detecting physiological thiol-containing compounds, including but are not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes, In one embodiment, thiol is detected by fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[0068] X is a nitrogen atom;

[0069] Y is a carbon atom;

[0070] R₁₀, R₁₁ are each lone electron pairs;

[0071] $R_1, R_2, R_3, R_4, R_7, R_8, R_9$ are each $-H$;

[0072] R_5, R_6 are each $-CH_3$;

[0073] n is $+1$, and

[0074] yA^b is $CF_3SO_3^-$. (Complex 1)

[0075] In another embodiment, described herein is a pharmaceutical composition for treatment or prevention of cancer/tumor. In certain embodiment, the treatment or prevention comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. The method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method detects physiological thiol-containing compounds which includes, but not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the detection comprises fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[0076] X is a nitrogen atom;

[0077] Y is a carbon atom;

[0078] R_{10}, R_{11} are each lone electron pairs;

[0079] $R_1, R_2, R_3, R_4, R_7, R_8, R_9$ are each $-H$;

[0080] R_5 is $-CH_3$;

[0081] R_6 is $-C_4H_9$;

[0082] n is $+1$, and

[0083] yA^b is $CF_3SO_3^-$. (Complex 2)

[0084] In another embodiment, provided herein is a pharmaceutical composition for treatment or prevention of cancer/tumor. The method includes for example, induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. The method comprises administering an effective amount of the Au(III)-NHC complexes to a subject. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the detection comprises fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[0085] X is a nitrogen atom;

[0086] Y is a carbon atom;

[0087] R₁₀, R₁₁ are each lone electron pairs;

[0088] R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;

[0089] R₅ is -CH₃;

[0090] R₆ is -C₈H₁₇;

[0091] n is +1, and

[0092] yA^b is CF₃SO₃⁻. (Complex 3)

[0093] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiment, the treatment and prevention comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In an embodiment, the method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one

embodiment, the method comprises detecting physiological thiol-containing compounds including, but not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the detection comprises fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[0094] X is a nitrogen atom;

[0095] Y is a carbon atom;

[0096] R₁₀, R₁₁ are each lone electron pairs;

[0097] R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;

[0098] R₅ is -CH₃;

[0099] R₆ is -C₁₀H₂₁;

[00100] n is +1, and

[00101] yA^b is CF₃SO₃⁻. (Complex **4**)

[00102] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiment, the treatment and prevention comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. The method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In an embodiment, the method comprises detecting physiological thiol-containing compounds including, but are not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises fluorescence changes at proper wavelength. In one embodiment, the Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00103] X is a nitrogen atom;

[00104] Y is a carbon atom;

[00105] R₁₀, R₁₁ are each lone electron pairs;

[00106] R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;

[00107] R₅ is -CH₃;

[00108] R₆ is -C₁₆H₃₃;

[00109] n is +1, and

[00110] yA^b is CF₃SO₃⁻. (Complex 5)

[00111] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiments, the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In one embodiment, the method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment; the method comprises detecting physiological thiol-containing compounds including, but are not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises fluorescence changes at proper wavelength. In one embodiment, the Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00112] X is a nitrogen atom;

[00113] Y is a carbon atom;

[00114] R₁₀, R₁₁ are each lone electron pairs;

[00115] R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;

[00116] R₅, R₆ are each -C₄H₉;

[00117] n is +1, and

[00118] yA^b is $CF_3SO_3^-$. (Complex 6)

[00119] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiments, the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In one embodiment, the method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but are not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00120] X is a nitrogen atom;

[00121] Y is a carbon atom;

[00122] R_{10} , R_{11} are each lone electron pairs;

[00123] R_1 , R_2 , R_3 , R_4 , R_7 , R_8 , R_9 are each $-H$;

[00124] R_5 , R_6 are each $-C_6H_{13}$;

[00125] n is +1, and

[00126] yA^b is $CF_3SO_3^-$. (Complex 7)

[00127] In another embodiment, provided herein is a pharmaceutical composition for treatment or prevention of cancer/tumor. In certain embodiments, the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In one embodiment, the method comprises

administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00128] X is a nitrogen atom;

[00129] Y is a carbon atom;

[00130] R₁₀, R₁₁ are each lone electron pairs;

[00131] R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;

[00132] R₅ is -CH₃;

[00133] R₆ is -C₃H₆PPh₃⁺;

[00134] n is +2, and

[00135] yA^b is 2CF₃SO₃⁻. (Complex **8**)

[00136] In another embodiment, described herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiments, the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In an embodiment, the method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but are not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting fluorescence changes at proper

wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00137] X is a nitrogen atom;

[00138] Y is a carbon atom;

[00139] Each pair of R₁ and R₃, and R₂ and R₄ is joined together to form



[00140] R₇, R₈, R₉ are each -H;

[00141] R₁₀, R₁₁ are each lone electron pairs;

[00142] R₅, R₆ are each -CH₃;

[00143] n is +1, and

[00144] yA^b is CF₃SO₃⁻. (Complex 9)

[00145] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiments, the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In one embodiment, the method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00146] X is a nitrogen atom;

[00147] Y is a carbon atom;

[00148] Each pair of R₁ and R₃, and R₂ and R₄ is joined together to form



[00149] R₇, R₈, R₉ are each -H;

[00150] R₁₀, R₁₁ are each lone electron pairs;

[00151] R₅, R₆ are each -C₄H₉;

[00152] n is +1, and

[00153] yA^b is CF₃SO₃⁻. (Complex 10)

[00154] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiments, the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In one embodiment, the method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00155] X is a nitrogen atom;

[00156] Y is a carbon atom;

[00157] Each pair of R₁ and R₃, and R₂ and R₄ is joined together to form



[00158] R₇, R₈, R₉ are each -H;

- [00159] R_{10}, R_{11} are each lone electron pairs;
- [00160] R_5, R_6 are each $-C_6H_{13}$;
- [00161] n is +1, and
- [00162] yA^b is $CF_3SO_3^-$. (Complex 11)
- [00163] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiments, the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In one embodiment, the method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,
- [00164] X is a carbon atom;
- [00165] Y is a nitrogen atom;
- [00166] R_3, R_4 are each lone electron pairs;
- [00167] $R_1, R_2, R_7, R_8, R_9, R_{10}, R_{11}$ are each $-H$;
- [00168] R_5, R_6 are each $-CH_3$;
- [00169] n is +1, and
- [00170] yA^b is $CF_3SO_3^-$. (Complex 12)
- [00171] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiment,

the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In an embodiment, the method comprises administration to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula **I**, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00172] X is a carbon atom;

[00173] Y is a nitrogen atom;

[00174] R₃, R₄ are each lone electron pairs;

[00175] R₁, R₂, R₇, R₈, R₉, R₁₀, R₁₁ are each -H;

[00176] R₅ is -CH₃;

[00177] R₆ is -C₄H₉;

[00178] n is +1, and

[00179] yA^b is CF₃SO₃⁻. (Complex 13)

[00180] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiments, the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In one embodiment, the method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but not limited to, cysteine(Cys), glutathione (GSH),

dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula I, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00181] X is a carbon atom;

[00182] Y is a nitrogen atom;

[00183] R₃, R₄ are each lone electron pairs;

[00184] R₁, R₂, R₇, R₈, R₉, R₁₀, R₁₁ are each -H;

[00185] R₅ is -CH₃;

[00186] R₆ is -C₁₆H₃₃;

[00187] n is +1, and

[00188] yA^b is CF₃SO₃⁻. (Complex 14)

[00189] In another embodiment, provided herein is a pharmaceutical composition for treatment and prevention of cancer/tumor. In certain embodiments, the method comprises induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase and/or poisoning of thioredoxin reductase, and the inhibition of tumor growth *in vivo*. In one embodiment, the method comprises administering to a subject an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting physiological thiol-containing compounds including, but not limited to, cysteine(Cys), glutathione (GSH), dithiothreitol (DTT), with an effective amount of the Au(III)-NHC complexes. In one embodiment, the method comprises detecting fluorescence changes at proper wavelength. The Au(III)-NHC complex has a formula I, derivatives thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein,

[00190] X is a carbon atom;

[00191] Y is a nitrogen atom;

[00192] R_3, R_4 are each lone electron pairs;

[00193] $R_1, R_2, R_9, R_{10}, R_{11}$ are each $-H$;

[00194] R_7 and R_8 are joined together to form



[00195] R_5, R_6 are each $-CH_3$;

[00196] n is $+1$, and

[00197] yA^b is $CF_3SO_3^-$. (Complex 15)

5.1 Human Treatment

5.1.1 Formulations

[00198] The gold(III) complexes containing N-heterocyclic carbene ligand provided herein can be administered to a patient in the conventional form of preparations, such as injections and suspensions. Suitable formulations can be prepared by methods commonly employed using conventional, organic or inorganic additives, such as an excipient selected from fillers or diluents, binders, disintegrants, lubricants, flavoring agents, preservatives, stabilizers, suspending agents, dispersing agents, surfactants, antioxidants or solubilizers.

[00199] Excipients that may be selected are known to those skilled in the art and include, but are not limited to fillers or diluents (*e.g.*, sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate and the like), a binder (*e.g.*, cellulose, carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, polyethyleneglycol or starch and the like), a disintegrants (*e.g.*, sodium starch glycolate, croscarmellose sodium and the like), a lubricant (*e.g.*, magnesium stearate, light anhydrous silicic acid, talc or sodium lauryl

sulfate and the like), a flavoring agent (*e.g.*, citric acid, or menthol and the like), a preservative (*e.g.*, sodium benzoate, sodium bisulfite, methylparaben or propylparaben and the like), a stabilizer (*e.g.*, citric acid, sodium citrate or acetic acid and the like), a suspending agent (*e.g.*, methylcellulose, polyvinyl pyrrolidone or aluminum stearate and the like), a dispersing agent (*e.g.*, hydroxypropylmethylcellulose and the like), surfactants (*e.g.*, sodium lauryl sulfate, polaxamer, polysorbates and the like), antioxidants (*e.g.*, ethylene diamine tetraacetic acid (EDTA), butylated hydroxyl toluene (BHT) and the like) and solubilizers (*e.g.*, polyethylene glycols, SOLUTOL[®], GELUCIRE[®] and the like). The effective amount of the gold(III) complexes containing N-heterocyclic carbene ligand provided herein in the pharmaceutical composition may be at a level that will exercise the desired effect.

[00200] In another embodiment, provided herein are compositions comprising an effective amount of gold(III) complexes containing N-heterocyclic carbene ligand provided herein and a pharmaceutically acceptable carrier or vehicle, wherein a pharmaceutically acceptable carrier or vehicle can comprise an excipient, diluent, or a mixture thereof. In one embodiment, the composition is a pharmaceutical composition.

[00201] Compositions can be formulated to contain a daily dose, or a convenient fraction of a daily dose, in a dosage unit. In general, the composition is prepared according to known methods in pharmaceutical chemistry. Capsules can be prepared by mixing the gold (III) complexes containing N-heterocyclic carbene ligand provided herein with a suitable carrier or diluent and filling the proper amount of the mixture in capsules.

5.2 Method of Use

[00202] Solid tumor cancers that can be treated by the methods provided herein include, but are not limited to, sarcomas, carcinomas, and lymphomas. In specific

embodiments, cancers that can be treated in accordance with the methods described include, but are not limited to, cancer of the breast, liver, neuroblastoma, head, neck, eye, mouth, throat, esophagus, esophagus, chest, bone, lung, kidney, colon, rectum or other gastrointestinal tract organs, stomach, spleen, skeletal muscle, subcutaneous tissue, prostate, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, and brain or central nervous system.

[00203] In particular embodiments, the methods for treating cancer provided herein inhibit, reduce, diminish, arrest, or stabilize a tumor associated with the cancer. In other embodiments, the methods for treating cancer provided herein inhibit, reduce, diminish, arrest, or stabilize the blood flow, metabolism, or edema in a tumor associated with the cancer or one or more symptoms thereof. In specific embodiments, the methods for treating cancer provided herein cause the regression of a tumor, tumor blood flow, tumor metabolism, or peritumor edema, and/or one or more symptoms associated with the cancer. In other embodiments, the methods for treating cancer provided herein maintain the size of the tumor so that it does not increase, or so that it increases by less than the increase of a tumor after administration of a standard therapy as measured by conventional methods available to one of skill in the art, such as digital rectal exam, ultrasound (*e.g.*, transrectal ultrasound), CT Scan, MRI, dynamic contrast-enhanced MRI, or PET Scan. In specific embodiments, the methods for treating cancer provided herein decrease tumor size. In certain embodiments, the methods for treating cancer provided herein reduce the formation of a tumor. In certain embodiments, the methods for treating cancer provided herein eradicate, remove, or control primary, regional and/or metastatic tumors associated with the cancer. In some embodiments, the methods for treating cancer provided herein decrease the number or size of metastases associated with the cancer.

[00204] In certain embodiments, the methods for treating cancer provided herein reduce the tumor size (*e.g.*, volume or diameter) in a subject by at least about

5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45 %, 50%, 55%, 60%, 65%, 80%, 85%, 90%, 95 %, 99%, or 100%, relative to tumor size (*e.g.*, volume or diameter) prior to administration of gold(III) complexes containing N-heterocyclic carbene ligand as assessed by methods well known in the art, *e.g.*, CT Scan, MRI, DCE-MRI, or PET Scan. In particular embodiments, the methods for treating cancer provided herein reduce the tumor volume or tumor size (*e.g.*, diameter) in a subject by an amount in the range of about 5% to 20%, 10% to 20%, 10% to 30%, 15% to 40%, 15% to 50%, 20% to 30%, 20% to 40%, 20% to 50%, 30% to 60%, 30% to 70%, 30% to 80%, 30% to 90%, 30% to 95%, 30% to 99%, 30% to 100%, or any range in between, relative to tumor size (*e.g.*, diameter) in a subject prior to administration of gold(III) complexes containing N-heterocyclic carbene ligand as assessed by methods well known in the art, *e.g.*, CT Scan, MRI, DCE-MRI, or PET Scan.

[00205] In certain embodiments, the methods for treating cancer provided herein reduce the tumor perfusion in a subject by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45 %, 50%, 55%, 60%, 65%, 80%, 85%, 90%, 95 %, 99%, or 100%, relative to tumor perfusion prior to administration of gold(III) complexes containing N-heterocyclic carbene ligand as assessed by methods well known in the art, *e.g.*, MRI, DCE-MRI, or PET Scan. In particular embodiments, the methods for treating cancer provided herein reduce the tumor perfusion in a subject by an amount in the range of about 5% to 20%, 10% to 20%, 10% to 30%, 15% to 40%, 15% to 50%, 20% to 30%, 20% to 40%, 20% to 50%, 30% to 60%, 30% to 70%, 30% to 80%, 30% to 90%, 30% to 95%, 30% to 99%, 30% to 100%, or any range in between, relative to tumor perfusion prior to administration of gold(III) complexes containing N-heterocyclic carbene ligand, as assessed by methods well known in the art, *e.g.*, MRI, DCE-MRI, or PET Scan.

[00206] In particular aspects, the methods for treating cancer provided herein inhibit or decrease tumor metabolism in a subject as assessed by methods well known in the art, *e.g.*, PET scanning. In specific embodiments, the methods for treating

cancer provided herein inhibit or decrease tumor metabolism in a subject by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45 %, 50%, 55%, 60%, 65%, 80%, 85%, 90%, 95 %, or 100%, relative to tumor metabolism prior to administration of gold(III) complexes containing N-heterocyclic carbene ligand, as assessed by methods well known in the art, *e.g.*, PET scanning. In particular embodiments, the methods for treating cancer provided herein inhibit or decrease tumor metabolism in a subject in the range of about 5% to 20%, 10% to 20%, 10% to 30%, 15% to 40%, 15% to 50%, 20% to 30%, 20% to 40%, 20% to 50%, 30% to 60%, 30% to 70%, 30% to 80%, 30% to 90%, 30% to 95%, 30% to 99%, 30% to 100%, or any range in between, relative to tumor metabolism prior to administration of gold(III) complexes containing N-heterocyclic carbene ligand, as assessed by methods well known in the art, *e.g.*, PET scan.

5.3 Patient Population

[00207] In some embodiments, a subject treated for cancer in accordance with the methods provided herein is a human who has or is diagnosed with cancer. In other embodiments, a subject treated for cancer in accordance with the methods provided herein is a human predisposed or susceptible to cancer. In some embodiments, a subject treated for cancer in accordance with the methods provided herein is a human at risk of developing cancer.

[00208] In one embodiment, a subject treated for cancer in accordance with the methods provided herein is a human infant. In another embodiment, a subject treated for cancer in accordance with the methods provided herein is a human toddler. In another embodiment, a subject treated for cancer in accordance with the methods provided herein is a human child. In another embodiment, a subject treated for cancer in accordance with the methods provided herein is a human adult. In another embodiment, a subject treated for cancer in accordance with the methods provided

herein is a middle-aged human. In another embodiment, a subject treated for cancer in accordance with the methods provided herein is an elderly human.

[00209] In certain embodiments, a subject treated for cancer in accordance with the methods provided herein has a cancer that metastasized to other areas of the body, such as the bones, lung and liver. In certain embodiments, a subject treated for cancer in accordance with the methods provided herein is in remission from the cancer. In some embodiments, a subject treated for cancer in accordance with the methods provided herein that has a recurrence of the cancer. In certain embodiments, a subject treated in accordance with the methods provided herein is experiencing recurrence of one or more tumors associated with cancer.

[00210] In certain embodiments, a subject treated for cancer in accordance with the methods provided herein is a human that is about 1 to about 5 years old, about 5 to 10 years old, about 10 to about 18 years old, about 18 to about 30 years old, about 25 to about 35 years old, about 35 to about 45 years old, about 40 to about 55 years old, about 50 to about 65 years old, about 60 to about 75 years old, about 70 to about 85 years old, about 80 to about 90 years old, about 90 to about 95 years old or about 95 to about 100 years old, or any age in between. In a specific embodiment, a subject treated for cancer in accordance with the methods provided herein is a human that is 18 years old or older. In a particular embodiment, a subject treated for cancer in accordance with the methods provided herein is a human child that is between the age of 1 year old to 18 years old. In a certain embodiment, a subject treated for cancer in accordance with the methods provided herein is a human that is between the age of 12 years old and 18 years old. In a certain embodiment, the subject is a male human. In another embodiment, the subject is a female human. In one embodiment, the subject is a female human that is not pregnant or is not breastfeeding. In one embodiment, the subject is a female that is pregnant or will/might become pregnant, or is breast feeding.

[00211] In some embodiments, a subject treated for cancer in accordance with the methods provided herein is administered gold(III) complexes containing N-heterocyclic carbene ligand or a pharmaceutical composition thereof, or a combination therapy before any adverse effects or intolerance to therapies other than the gold(III) complexes containing N-heterocyclic carbene ligand develops. In some embodiments, a subject treated for cancer in accordance with the methods provided herein is a refractory patient. In a certain embodiment, a refractory patient is a patient refractory to a standard therapy (*e.g.*, surgery, radiation, anti-androgen therapy and/or drug therapy such as chemotherapy). In certain embodiments, a patient with cancer is refractory to a therapy when the cancer has not significantly been eradicated and/or the one or more symptoms have not been significantly alleviated. The determination of whether a patient is refractory can be made either *in vivo* or *in vitro* by any method known in the art for assaying the effectiveness of a treatment of cancer, using art-accepted meanings of “refractory” in such a context. In various embodiments, a patient with cancer is refractory when one or more tumors associated with cancer, have not decreased or have increased. In various embodiments, a patient with cancer is refractory when one or more tumors metastasize and/or spread to another organ.

[00212] In some embodiments, a subject treated for cancer accordance with the methods provided herein is a human that has proven refractory to therapies other than treatment with gold(III) complexes containing N-heterocyclic carbene ligand, but is no longer on these therapies. In certain embodiments, a subject treated for cancer in accordance with the methods provided herein is a human already receiving one or more conventional anti-cancer therapies, such as surgery, drug therapy such as chemotherapy, anti-androgen therapy or radiation. Among these patients are refractory patients, patients who are too young for conventional therapies, and patients with recurring tumors despite treatment with existing therapies.

5.4 Dosage

[00213] In one aspect, a method for treating cancer presented herein involves the administration of a unit dosage of gold(III) complexes containing N-heterocyclic carbene ligand thereof. The dosage may be administered as often as determined effective (*e.g.*, once, twice or three times per day, every other day, once or twice per week, biweekly or monthly). In certain embodiments, a method for treating cancer presented herein involves the administration to a subject in need thereof of a unit dose of gold(III) complexes containing N-heterocyclic carbene ligand that can be determined by one skilled in the art.

[00214] In some embodiments, a unit dose of gold(III) complexes containing N-heterocyclic carbene ligand or a pharmaceutical composition thereof is administered to a subject once per day, twice per day, three times per day; once, twice or three times every other day (*i.e.*, on alternate days); once, twice or three times every two days; once, twice or three times every three days; once, twice or three times every four days; once, twice or three times every five days; once, twice, or three times once a week, biweekly or monthly, and the dosage may be administered orally.

5.5 Combination Therapy

[00215] Presented herein are combination therapies for the treatment of cancer which involve the administration of gold(III) complexes containing N-heterocyclic carbene ligand in combination with one or more additional therapies to a subject in need thereof. In a specific embodiment, presented herein are combination therapies for the treatment of cancer which involve the administration of an effective amount of gold(III) complexes containing N-heterocyclic carbene ligand in combination with an effective amount of another therapy to a subject in need thereof.

[00216] As used herein, the term "in combination," refers, in the context of the administration of gold(III) complexes containing N-heterocyclic carbene ligand, to the administration of gold(III) complexes containing N-heterocyclic carbene ligand prior

to, concurrently with, or subsequent to the administration of one or more additional therapies (e.g., agents, surgery, or radiation) for use in treating cancer. The use of the term “in combination” does not restrict the order in which gold(III) complexes containing N-heterocyclic carbene ligand and one or more additional therapies are administered to a subject. In specific embodiments, the interval of time between the administration of gold(III) complexes containing N-heterocyclic carbene ligand and the administration of one or more additional therapies may be about 1-5 minutes, 1-30 minutes, 30 minutes to 60 minutes, 1 hour, 1-2 hours, 2-6 hours, 2-12 hours, 12-24 hours, 1-2 days, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 26 weeks, 52 weeks, 11-15 weeks, 15-20 weeks, 20-30 weeks, 30-40 weeks, 40-50 weeks, 1 month, 2 months, 3 months, 4 months 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, or any period of time in between. In certain embodiments, gold(III) complexes containing N-heterocyclic carbene ligand and one or more additional therapies are administered less than 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, one month, 2 months, 3 months, 6 months, 1 year, 2 years, or 5 years apart.

[00217] In some embodiments, the combination therapies provided herein involve administering gold(III) complexes containing N-heterocyclic carbene ligand daily, and administering one or more additional therapies once a week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every month, once every 2 months (e.g., approximately 8 weeks), once every 3 months (e.g., approximately 12 weeks), or once every 4 months (e.g., approximately 16 weeks). In certain embodiments, gold(III) complexes containing N-heterocyclic carbene ligand and one or more additional therapies are cyclically administered to a subject. Cycling therapy involves the administration of gold(III) complexes containing N-heterocyclic carbene ligand for a period of time, followed by the administration of one or more additional therapies for a period of time, and repeating this sequential administration.

In certain embodiments, cycling therapy may also include a period of rest where gold(III) complexes containing N-heterocyclic carbene ligand or the additional therapy is not administered for a period of time (e.g., 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 10 weeks, 20 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 2 years, or 3 years). In an embodiment, the number of cycles administered is from 1 to 12 cycles, from 2 to 10 cycles, or from 2 to 8 cycles.

[00218] In some embodiments, the methods for treating cancer provided herein comprise administering gold(III) complexes containing N-heterocyclic carbene ligand as a single agent for a period of time prior to administering the gold(III) complexes containing N-heterocyclic carbene ligand in combination with an additional therapy. In certain embodiments, the methods for treating cancer provided herein comprise administering an additional therapy alone for a period of time prior to administering gold(III) complexes containing N-heterocyclic carbene ligand in combination with the additional therapy.

[00219] In some embodiments, the administration of gold(III) complexes containing N-heterocyclic carbene ligand and one or more additional therapies in accordance with the methods presented herein have an additive effect relative the administration of gold(III) complexes containing N-heterocyclic carbene ligand or said one or more additional therapies alone. In some embodiments, the administration of gold(III) complexes containing N-heterocyclic carbene ligand and one or more additional therapies in accordance with the methods presented herein have a synergistic effect relative to the administration of the Compound or said one or more additional therapies alone.

[00220] As used herein, the term “synergistic,” refers to the effect of the administration of gold(III) complexes containing N-heterocyclic carbene ligand in combination with one or more additional therapies (e.g., agents), which combination

is more effective than the additive effects of any two or more single therapies (e.g., agents). In a specific embodiment, a synergistic effect of a combination therapy permits the use of lower dosages (e.g., sub-optimal doses) of gold(III) complexes containing N-heterocyclic carbene ligand or an additional therapy and/or less frequent administration of gold(III) complexes containing N-heterocyclic carbene ligand or an additional therapy to a subject. In certain embodiments, the ability to utilize lower dosages of gold(III) complexes containing N-heterocyclic carbene ligand or of an additional therapy and/or to administer gold(III) complexes containing N-heterocyclic carbene ligand or said additional therapy less frequently reduces the toxicity associated with the administration of gold(III) complexes containing N-heterocyclic carbene ligand or of said additional therapy, respectively, to a subject without reducing the efficacy of gold(III) complexes containing N-heterocyclic carbene ligand or of said additional therapy, respectively, in the treatment of cancer. In some embodiments, a synergistic effect results in improved efficacy of gold(III) complexes containing N-heterocyclic carbene ligand and each of said additional therapies in treating cancer. In some embodiments, a synergistic effect of a combination of gold(III) complexes containing N-heterocyclic carbene ligand and one or more additional therapies avoids or reduces adverse or unwanted side effects associated with the use of any single therapy.

[00221] The combination of gold(III) complexes containing N-heterocyclic carbene ligand and one or more additional therapies can be administered to a subject in the same pharmaceutical composition. Alternatively, gold(III) complexes containing N-heterocyclic carbene ligand and one or more additional therapies can be administered concurrently to a subject in separate pharmaceutical compositions. Gold(III) complexes containing N-heterocyclic carbene ligand and one or more additional therapies can be administered sequentially to a subject in separate pharmaceutical compositions. Gold(III) complexes containing N-heterocyclic

carbene ligand and one or more additional therapies may also be administered to a subject by the same or different routes of administration.

[00222] The combination therapies provided herein involve administering to a subject to in need thereof gold(III) complexes containing N-heterocyclic carbene ligand in combination with conventional, or known, therapies for treating cancer. Other therapies for cancer or a condition associated therewith are aimed at controlling or relieving one or more symptoms. Accordingly, in some embodiments, the combination therapies provided herein involve administering to a subject to in need thereof a pain reliever, or other therapies aimed at alleviating or controlling one or more symptoms associated with or a condition associated therewith.

[00223] Specific examples of anti-cancer agents that may be used in combination with gold(III) complexes containing N-heterocyclic carbene ligand include: a hormonal agent (e.g., aromatase inhibitor, selective estrogen receptor modulator (SERM), and estrogen receptor antagonist), chemotherapeutic agent (e.g., microtubule disassembly blocker, antimetabolite, topoisomerase inhibitor, and DNA crosslinker or damaging agent), anti-angiogenic agent (e.g., VEGF antagonist, receptor antagonist, integrin antagonist, vascular targeting agent (VTA)/vascular disrupting agent (VDA)), radiation therapy, and conventional surgery.

[00224] Non-limiting examples of hormonal agents that may be used in combination with gold(III) complexes containing N-heterocyclic carbene ligand include aromatase inhibitors, SERMs, and estrogen receptor antagonists. Hormonal agents that are aromatase inhibitors may be steroidal or nonsteroidal. Non-limiting examples of nonsteroidal hormonal agents include letrozole, anastrozole, aminoglutethimide, fadrozole, and vorozole. Non-limiting examples of steroidal hormonal agents include aromasin (exemestane), formestane, and testolactone. Non-limiting examples of hormonal agents that are SERMs include tamoxifen (branded/ marketed as Nolvadex®), afimoxifene, arzoxifene, bazedoxifene, clomifene, femarelle, lasofoxifene, ormeloxifene, raloxifene, and toremifene. Non-limiting

examples of hormonal agents that are estrogen receptor antagonists include fulvestrant. Other hormonal agents include but are not limited to abiraterone and lonaprisan.

[00225] Non-limiting examples of chemotherapeutic agents that may be used in combination with gold(III) complexes containing N-heterocyclic carbene ligand include microtubule disassembly blocker, antimetabolite, topoisomerase inhibitor, and DNA crosslinker or damaging agent. Chemotherapeutic agents that are microtubule disassembly blockers include, but are not limited to, taxenes (e.g., paclitaxel (branded/marketed as TAXOL®), docetaxel, abraxane, larotaxel, ortataxel, and tesetaxel); epothilones (e.g., ixabepilone); and vinca alkaloids (e.g., vinorelbine, vinblastine, vindesine, and vincristine (branded/marketed as ONCOVIN®)).

[00226] Chemotherapeutic agents that are antimetabolites include, but are not limited to, folate antimetabolites (e.g., methotrexate, aminopterin, pemetrexed, raltitrexed); purine antimetabolites (e.g., cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, thioguanine); pyrimidine antimetabolites (e.g., 5-fluorouracil, capecitabine, gemcitabine (GEMZAR®), cytarabine, decitabine, floxuridine, tegafur); and deoxyribonucleotide antimetabolites (e.g., hydroxyurea).

[00227] Chemotherapeutic agents that are topoisomerase inhibitors include, but are not limited to, class I (camptotheca) topoisomerase inhibitors (e.g., topotecan (branded/marketed as Hycamtin®) irinotecan, rubitecan, and belotecan); class II (podophyllum) topoisomerase inhibitors (e.g., etoposide or VP-16, and teniposide); anthracyclines (e.g., doxorubicin, epirubicin, Doxil, aclarubicin, amrubicin, daunorubicin, idarubicin, pirarubicin, valrubicin, and zorubicin); and anthracenediones (e.g., mitoxantrone, and pixantrone).

[00228] Chemotherapeutic agents that are DNA crosslinkers (or DNA damaging agents) include, but are not limited to, alkylating agents (e.g., cyclophosphamide, mechlorethamine, ifosfamide (branded/marketed as IFEX®), trofosfamide, chlorambucil, melphalan, prednimustine, bendamustine, uramustine,

estramustine, carmustine (branded/ marketed as BiCNU®), lomustine, semustine, fotemustine, nimustine, ranimustine, streptozocin, busulfan, mannosulfan, treosulfan, carboquone, N,N'N'-triethylenethiophosphoramidate, triaziquone, triethylenemelamine); alkylating-like agents (e.g., carboplatin (branded/ marketed as PARAPLATIN®), cisplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, satraplatin, picoplatin); nonclassical DNA crosslinkers (e.g., procarbazine, dacarbazine, temozolomide (branded/ marketed as TEMODAR®), altretamine, mitobronitol); and intercalating agents (e.g., actinomycin, bleomycin, mitomycin, and plicamycin).

[00229] Non-limiting examples of other therapies that may be administered to a subject in combination with gold(III) complexes containing N-heterocyclic carbene ligand include:

[00230] (1) a statin such as lovostatin (*e.g.*, branded/ marketed as MEVACOR®);

[00231] (2) an mTOR inhibitor such as sirolimus which is also known as Rapamycin (*e.g.*, branded/ marketed as RAPAMUNE®), temsirolimus (*e.g.*, branded/ marketed as TORISEL®), everolimus (*e.g.*, branded/ marketed as AFINITOR®), and deforolimus;

[00232] (3) a farnesyltransferase inhibitor agent such as tipifarnib;

[00233] (4) an antifibrotic agent such as pirfenidone;

[00234] (5) a pegylated interferon such as PEG-interferon alfa-2b;

[00235] (6) a CNS stimulant such as methylphenidate (branded/ marketed as RITALIN®);

[00236] (7) a HER-2 antagonist such as anti-HER-2 antibody (*e.g.*, trastuzumab) and kinase inhibitor (*e.g.*, lapatinib);

[00237] (8) an IGF-1 antagonist such as an anti-IGF-1 antibody (*e.g.*, AVE1642 and IMC-A11) or an IGF-1 kinase inhibitor;

- [00238] (9) EGFR/HER-1 antagonist such as an anti-EGFR antibody (*e.g.*, cetuximab, panitumumab) or EGFR kinase inhibitor (*e.g.*, erlotinib; gefitinib);
- [00239] (10) SRC antagonist such as bosutinib;
- [00240] (11) cyclin dependent kinase (CDK) inhibitor such as seliciclib;
- [00241] (12) Janus kinase 2 inhibitor such as lestaurtinib;
- [00242] (13) proteasome inhibitor such as bortezomib;
- [00243] (14) phosphodiesterase inhibitor such as anagrelide;
- [00244] (15) inosine monophosphate dehydrogenase inhibitor such as tiazofurine;
- [00245] (16) lipoxygenase inhibitor such as masoprocol;
- [00246] (17) endothelin antagonist;
- [00247] (18) retinoid receptor antagonist such as tretinoin or alitretinoin;
- [00248] (19) immune modulator such as lenalidomide, pomalidomide, or thalidomide;
- [00249] (20) kinase (*e.g.*, tyrosine kinase) inhibitor such as imatinib, dasatinib, erlotinib, nilotinib, gefitinib, sorafenib, sunitinib, lapatinib, or TG100801;
- [00250] (21) non-steroidal anti-inflammatory agent such as celecoxib (branded/ marketed as CELEBREX[®]);
- [00251] (22) human granulocyte colony-stimulating factor (G-CSF) such as filgrastim (branded/ marketed as NEUPOGEN[®]);
- [00252] (23) folic acid or leucovorin calcium;
- [00253] (24) integrin antagonist such as an integrin $\alpha 5\beta 1$ -antagonist (*e.g.*, JSM6427);

- [00254] (25) nuclear factor kappa beta (NF- κ β) antagonist such as OT-551, which is also an anti-oxidant;
- [00255] (26) hedgehog inhibitor such as CUR61414, cyclopamine, GDC-0449, and anti-hedgehog antibody;
- [00256] (27) histone deacetylase (HDAC) inhibitor such as SAHA (also known as vorinostat (branded/ marketed as ZOLINZA)), PCI-24781, SB939, CHR-3996, CRA-024781, ITF2357, JNJ-26481585, or PCI-24781;
- [00257] (28) retinoid such as isotretinoin (*e.g.*, branded/ marketed as ACCUTANE®);
- [00258] (29) hepatocyte growth factor/scatter factor (HGF/SF) antagonist such as HGF/SF monoclonal antibody (*e.g.*, AMG 102);
- [00259] (30) synthetic chemical such as antineoplaston;
- [00260] (31) anti-diabetic such as rosiglitazone (*e.g.*, branded/ marketed as AVANDIA®);
- [00261] (32) antimalarial and amebicidal drug such as chloroquine (*e.g.*, branded/ marketed as ARALEN®);
- [00262] (33) synthetic bradykinin such as RMP-7;
- [00263] (34) platelet-derived growth factor receptor inhibitor such as SU-101;
- [00264] (35) receptor tyrosine kinase inhibitors of Flk-1/KDR/VEGFR2, FGFR1 and PDGFR beta such as SU5416 and SU6668;
- [00265] (36) anti-inflammatory agent such as sulfasalazine (*e.g.*, branded/ marketed as AZULFIDINE®); and
- [00266] (37) TGF-beta antisense therapy.


6. Examples

Example 6.1: Preparation and Characterization of the Au(III)-NHC Complexes

[00267] Example 1 illustrates the synthesis and characterization of the gold(III) complexes bearing N-heterocyclic carbene complexes.


[00268] PPP-Au-Cl was synthesized similar to a reported procedure [Acta Cryst.(2010). E66,m64].

[00269] Synthesis of IPI-Au-Cl



[00270] A mixture of H₂IPI (251.5 mg, 1.19 mmol), KAuCl₄ (300 mg, 0.794 mmol), and sodium acetate (325 mg, 3.97 mmol) was stirred in methanol (10 mL) at room temperature; red solid appeared in several seconds. After 2 h, the product was filtered and washed with methanol and then with diethyl ether. Yield 90 %; ¹H NMR (400 MHz, DMSO-d₆, 25 °C): δ = 8.22 (t, *J* = 7.9 Hz, 1 H), 7.63 (d, *J* = 7.9 Hz, 2 H), 7.33 (d, *J* = 0.72 Hz, 2 H), 7.31 (d, *J* = 0.70 Hz, 2 H); FAB-MS: *m/z* 442 [M + 1]⁺; Elemental analysis calcd (%) for C₁₁H₇AuClN₅: C, 29.92; H, 1.60; N, 15.86; found: C, 30.19; H, 1.77; N 15.71.


[00271] Synthesis of BPB-Au-Cl



[00272] A mixture of H₂BPB (165 mg, 0.53 mmol), KAuCl₄ (300 mg, 0.794 mmol), and sodium acetate (325 mg, 3.97 mmol) in methanol (25 mL) was heated to reflux for 2 h. The product was filtered and washed with methanol and then with diethyl ether. Yield 95 %; ¹H NMR (400 MHz, DMSO-d₆, 25 °C): δ = 8.51 (t, *J* = 7.9 Hz, 1H), 8.18 (d, *J* = 7.9 Hz, 2H), 8.14 (d, *J* = 8.1Hz, 2H), 7.78 (d, *J* = 8.0 Hz, 2H), 7.37 (m, 2H), 7.28 (m, 2H); FAB-MS: *m/z* 542 [M + 1]⁺; Elemental analyses calcd (%)


for $C_{19}H_{11}AuClN_5 \cdot H_2O$: C, 40.77; H, 2.34; N, 12.51; found: C, 40.29; H, 2.18; N, 12.39.

[00273] Synthesis of **1**




[00274] A mixture of IPI-Au-Cl (80 mg, 0.181 mmol), silver triflate (55.7 mg, 0.217 mmol), and (1,3-dimethyl-1*H*-imidazol-2(3*H*)-ylidene)silver(I) iodide (71.9 mg, 0.217 mmol) in acetonitrile (10 mL) was heated to reflux for 12 h in the dark. After cooling to room temperature, the reaction mixture was filtered, and the filtrate was purified by alumina with CH_3CN/CH_2Cl_2 as eluents, and yellow powder was obtained. Yield 45 %; 1H NMR (300 MHz, CD_3CN , 25 °C): δ = 8.24 (t, J = 7.9 Hz, 1H), 7.72 (d, J = 8.0 Hz, 2H), 7.57 (s, 2H), 7.25 (d, J = 0.9 Hz, 2H), 7.01 (d, J = 0.9 Hz, 2H), 3.93 (s, 6H); FAB-MS: m/z 502 $[M - OTf]^+$; Elemental analyses calcd (%) for $C_{17}H_{15}AuF_3N_7O_3S$: C, 31.35; H, 2.32; N, 15.05; found: C, 31.51; H, 2.45; N, 15.22.


[00275] Synthesis of **2**




[00276] The procedure is similar to that for **1**. Yield 60 %; 1H NMR (400 MHz, CD_3CN , 25 °C): δ = 8.24 (t, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 2.1 Hz, 1H), 7.59 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 0.9 Hz, 2H), 6.98 (d, J = 0.9 Hz, 2H), 4.25 (t, J = 7.3 Hz, 2H), 3.93 (s, 3H), 1.78 (m, 2H), 1.24 (m, 2H), 0.81 (t, J = 7.4 Hz, 3H); FAB-MS: m/z 544 $[M - OTf]^+$; Elemental analysis calcd (%) for $C_{20}H_{21}AuF_3N_7O_3S \cdot H_2O$: C, 33.76; H, 3.26; N, 13.78; found: C, 33.87; H, 3.24; N, 13.87.

[00277] Synthesis of **3**

[00278] The procedure is similar to that for **1**. Yield 45 %; ^1H NMR (400 MHz, CD_3CN , 25 °C): δ = 8.23 (t, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 2.1 Hz, 1H), 7.60 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 0.9 Hz, 2H), 6.99 (d, J = 0.9 Hz, 2H), 4.26 (t, J = 7.1 Hz, 2H), 3.94 (s, 3H), 1.80 (m, 2H), 1.17 (m, 6H), 1.11 (m, 4H), 0.82 (t, J = 7.2 Hz, 3H); FAB-MS: m/z 600 $[\text{M} - \text{OTf}]^+$; Elemental analysis calcd (%) for $\text{C}_{24}\text{H}_{29}\text{AuF}_3\text{N}_7\text{O}_3\text{S}$: C, 38.46; H, 3.90; N, 13.08; found: C, 38.45; H, 3.99; N, 13.00.

[00279] Synthesis of **4**


[00280] The procedure is similar to that for **1**. Yield 48 %; ^1H NMR (300 MHz, CD_3CN , 25 °C): δ = 8.24 (t, J = 8.0 Hz, 1H), 7.72 (d, J = 7.9 Hz, 2H), 7.62 (d, J = 2.7 Hz, 1H), 7.59 (d, J = 2.7 Hz, 1H), 7.25 (d, J = 0.9 Hz, 2H), 6.99 (d, J = 0.9 Hz, 2H), 4.25 (t, J = 7.1 Hz, 2H), 3.93 (s, 3H), 1.82 (m, 2H), 1.27–1.10 (m, 14H), 0.85 (t, J = 6.9 Hz, 3H); FAB-MS: m/z 628 $[\text{M} - \text{OTf}]^+$; Elemental analysis calcd (%) for $\text{C}_{26}\text{H}_{33}\text{AuF}_3\text{N}_7\text{O}_3\text{S}$: C, 40.16; H, 4.28; N, 12.61; found: C, 40.28, H, 4.42, N, 12.78.

[00281] Synthesis of **5**

[00282] The procedure is similar to that for **1**. Yield 45 %; ^1H NMR (300 MHz, CD_3CN , 25 °C): δ = 8.23 (t, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 2H), 7.63 (d, J = 2.0


Hz, 1H), 7.61 (d, $J = 2.0$ Hz, 1H), 7.23 (d, $J = 0.9$ Hz, 2H), 6.99 (d, $J = 0.9$ Hz, 2H), 4.26 (t, $J = 7.1$ Hz, 2H), 3.94 (s, 3H), 1.80 (m, 2H), 1.17–1.32 (m, 26H), 0.87 (t, $J = 7.2$ Hz, 3H); FAB-MS: m/z 712 [M - OTf]⁺; Elemental analysis calcd (%) for C₃₂H₄₅AuF₃N₇O₃S·H₂O: C, 43.69; H, 5.38; N, 11.14; found: C, 44.00; H, 5.50; N, 11.16.

[00283] Synthesis of **6**




[00284] The procedure is similar to that for **1**. Yield 52 %; ¹H NMR (400 MHz, CD₃CN, 25°C): $\delta = 8.23$ (t, $J = 7.9$ Hz, 1H), 7.71 (d, $J = 8.0$ Hz, 2H), 7.66 (s, 2H), 7.24 (d, $J = 1.0$ Hz, 2H), 6.95 (d, $J = 1.0$ Hz, 2H), 4.28 (t, $J = 7.3$ Hz, 4H), 1.79 (m, 4H), 1.25 (m, 4H), 0.81 (t, $J = 7.4$ Hz, 6H); FAB-MS: m/z 586 [M - OTf]⁺; Elemental Analysis calcd (%) for C₂₃H₂₇AuF₃N₇O₃S: C, 37.56; H, 3.70; N, 13.33; found: C, 38.04; H, 3.92; N, 13.09.

[00285] Synthesis of **7**




[00286] The procedure is similar to that for **1**. Yield 55 %; ¹H NMR (400 MHz, CD₃CN, 25°C): $\delta = 8.24$ (t, $J = 8.0$ Hz, 1H), 7.72 (d, $J = 8.0$ Hz, 2H), 7.65 (s, 2H), 7.24 (d, $J = 0.8$ Hz, 2H), 6.96 (d, $J = 0.8$ Hz, 2H), 4.26 (t, $J = 7.2$ Hz, 4H), 1.79 (m, 4H), 1.20–1.15 (m, 12H), 0.76 (t, $J = 6.9$ Hz, 6H); FAB-MS: m/z 642 [M - OTf]⁺; Elemental Analysis calcd (%) for C₂₇H₃₅AuF₃N₇O₃S: C, 40.96; H, 4.46; N, 12.39; found: C, 41.26; H, 4.51; N, 12.48.

[00287] Synthesis of **8**



[00288] 1-Methyl-3-(3-(triphenylphosphonio)propyl)-1*H*-imidazol-3-ium bromide was synthesized by refluxing the mixture of 1-methyl-1*H*-imidazole and (3-bromopropyl)triphenylphosphonium bromide (1:1) in ethanol for 12 h; after cooling down, the *solvent* was removed and the crude product was washed with ethyl acetate. Then the white product was treated with silver (I) oxide in CH_2Cl_2 for 12 h, and the crude Ag-NHC product was filtered and washed with CH_2Cl_2 and then with diethyl ether, and was used for the next step directly. The procedure for the synthesis of **3** is similar to that for **1**. Total yield 32 %; ^1H NMR (400 MHz, CD_3CN , 25 °C): δ = 8.21 (t, J = 8.0 Hz, 1H), 7.82 (m, 3H), 7.69–7.72 (m, 3H), 7.66 (d, J = 2.0 Hz, 1H), 7.55–7.63 (m, 12H), 7.17 (d, J = 0.9 Hz, 2H), 6.98 (d, J = 0.9 Hz, 2H), 4.57 (t, J = 7.1 Hz, 2H), 3.94 (s, 3H), 3.27 (m, 2H), 2.11 (m, 2H); FAB-MS: m/z 940 $[\text{M} - \text{OTf}]^+$; Elemental Analysis calcd (%) for $\text{C}_{38}\text{H}_{33}\text{AuF}_6\text{N}_7\text{O}_6\text{PS}_2 \cdot \text{H}_2\text{O}$: C, 41.20; H, 3.18; N, 8.85; found: C, 41.25; H, 3.29; N 8.72.


[00289] Synthesis of **9**



[00290] The procedure is similar to that for **1**. Yield 43 %; ^1H NMR (400 MHz, CD_3CN , 25 °C): δ = 8.51 (t, J = 7.9 Hz, 1H), 8.24 (d, J = 7.9 Hz, 2H), 7.85 (s, 2H), 7.80 (d, J = 8.2 Hz, 2H), 7.31–7.23 (m, 4H), 5.99 (d, J = 7.9 Hz, 2H), 4.01 (s, 6H); FAB-MS: m/z 602 $[\text{M} - \text{OTf}]^+$; Elemental Analysis calcd (%) for


$C_{25}H_{19}AuF_3N_7O_3S \cdot H_2O \cdot CH_2Cl_2$: C, 36.55; H, 2.71; N, 11.48; found: C, 36.46; H, 2.57; N, 11.34.

[00291] Synthesis of **10**




[00292] The procedure is similar to that for **1**. Yield 51 %; 1H NMR (300 MHz, CD_3CN , 25 °C): δ = 8.49 (t, J = 7.9 Hz, 1H), 8.24 (d, J = 7.9 Hz, 2H), 7.92 (s, 2H), 7.80 (d, J = 7.4 Hz, 2H), 7.31–7.20 (m, 4H), 5.91 (d, J = 8.6 Hz, 2H), 4.35 (t, J = 7.3 Hz, 4H), 1.71 (m, 4H), 1.24 (m, 4H), 0.59 (t, J = 7.3 Hz, 6H); FAB-MS: m/z 686 [M - OTf] $^+$; Elemental Analysis calcd (%) for $C_{31}H_{31}AuF_3N_7O_3S$: C, 44.56; H, 3.74; N, 11.73; found: C, 44.16; H, 3.84; N, 11.62.

[00293] Synthesis of **11**




[00294] The procedure is similar to that for **1**. Yield 55 %; 1H NMR (300 MHz, CD_3CN , 25°C): δ = 8.50 (t, J = 7.9 Hz, 1H), 8.24 (d, J = 8.0 Hz, 2H), 7.93 (s, 2H), 7.80 (d, J = 7.5 Hz, 2H), 7.31–7.20 (m, 4H), 5.93 (d, J = 7.0 Hz, 2H), 4.35 (t, J = 7.2 Hz, 4H), 1.73 (m, 4 H), 1.15 (m, 4 H), 0.89 (m, 8 H), 0.56 (t, J = 7.1 Hz, 6 H); FAB-MS: m/z 742 [M - OTf] $^+$; Elemental Analysis calcd (%) for $C_{35}H_{39}AuF_3N_7O_3S$: C, 47.14; H, 4.41; N, 10.99; found: C, 47.00, H, 4.46, N, 10.78.

[00295] Synthesis of **12**




[00296] The procedure is similar to that for **1**. Yield 40 %; ^1H NMR (400 MHz, CD_3CN , 25°C): $\delta = 8.27$ (t, $J = 8.0$ Hz, 1H), 7.76 (d, $J = 8.0$ Hz, 2H), 7.59 (d, $J = 2.0$ Hz, 2H), 7.52 (s, 2H), 6.93 (d, $J = 1.8$ Hz, 2H), 4.01 (s, 6H).

[00297] Synthesis of **13**




[00298] The procedure is similar to that for **1**. Yield 42 %; ^1H NMR (300 MHz, CD_3CN , 25°C): $\delta = 8.29$ (t, $J = 8.0$ Hz, 1H), 7.79 (d, $J = 8.0$ Hz, 2H), 7.62 (d, $J = 2.1$ Hz, 2H), 7.60 (d, $J = 2.0$ Hz, 1H), 7.57 (d, $J = 2.0$ Hz, 1H), 6.98 (d, $J = 2.1$ Hz, 2H), 4.33 (t, $J = 7.5$ Hz, 2H), 4.01 (s, 3H), 1.86 (m, 2H), 1.28 (m, 2H), 0.82 (t, $J = 7.4$ Hz, 3H).

[00299] Synthesis of **14**



[00300] The procedure is similar to that for **1**. Yield 38 %; ^1H NMR (400 MHz, CD_3CN , 25°C): $\delta = 8.27$ (t, $J = 8.0$ Hz, 1H), 7.76 (d, $J = 8.0$ Hz, 2H), 7.59 (d, $J = 2.1$ Hz, 2H), 7.57 (d, $J = 2.0$ Hz, 1H), 7.54 (d, $J = 1.9$ Hz, 1H), 6.95 (d, $J = 2.1$ Hz, 2H), 4.31 (t, $J = 7.3$ Hz, 2H), 3.99 (s, 3H), 1.86 (m, 2H), 1.30 – 1.07 (m, 26H), 0.88 (t, $J = 6.8$ Hz, 3H).

[00301] Synthesis of **15**



[00302] The procedure is similar to that for **1**. Yield 40 %; ^1H NMR (300 MHz, CD_3CN , 25°C): $\delta = 8.30$ (t, $J = 8.0$ Hz, 1H), 7.87–7.84 (m, 2H), 7.79 (d, $J = 8.0$ Hz, 2H), 7.69–7.65 (m, 2H), 7.59 (d, $J = 2.1$ Hz, 2H), 6.97 (d, $J = 2.1$ Hz, 2H), 4.23 (s, 6H).

Example 6.2: *In Vitro* Cytotoxicity of the Au(III)-NHC Complexes

[00303] Example 2 describes the *in vitro* cytotoxicity, which is indicative of the induction of cell death and/or inhibition of cellular proliferation of cancer cells, of the Au(III)-NHC complexes on cervical epithelioid carcinoma, hepatocellular carcinoma, leukemia, nasopharyngeal carcinoma, breast carcinoma, melanoma, and lung carcinoma.

[00304] By means of MTT assays, the cytotoxic properties of **1–11** were determined toward some established human cancer cell lines including hepatocellular carcinoma (HepG2), cervical epithelioid carcinoma (HeLa), lung carcinoma (NCI-H460), breast cancer (MCF-7), melanoma (B16) and nasopharyngeal carcinoma (SUNE1). The IC_{50} values (dose required to inhibit 50% cellular growth for 72 h) of the gold(III) complexes are listed in Table 1. All the Au(III)-NHC complexes exhibit promising cytotoxicity toward these cell lines with IC_{50} values range of 2 to 75 μM . In terms of the IC_{50} values, they display similar cytotoxic properties compared to the reference complexes cisplatin.

[00305] Table 1 Cytotoxicity IC₅₀ of the Au(III)-NHC complexes to selected human cancer cell lines

Complex	HeLa	HepG2	NCI-H460	MCF-7	SUNE1	B16
1	32.9 ± 1.3	36.2±2.2	55.0 ± 8.5	18.4 ± 0.3	28.7 ± 7.3	30.6 ± 0.3
2	15.7	33.2±1.8	11.0 ± 0.3	17.2 ± 0.6	9.9 ± 0.1	5.0 ± 0.2
3	14.0 ± 0.3	14.7±1.5	17.3 ± 0.3	8.5 ± 0.2	8.9 ± 0.6	3.8 ± 0.1
4	8.2	11.8±1.2	9.7 ± 0.4	6.5 ± 0.5	5.5 ± 0.3	1.6 ± 0.1
5	1.4 ± 0.2	3.3± 0.5	1.4 ± 0.1	2.9 ± 0.2	28.6 ± 0.3	2.2 ± 0.1
6	13.0 ± 1.6	28.7±5.9	7.9 ± 1.1	12.9± 2.0	9.9 ± 0.2	8.3 ± 0.2
7	8.2	9.1±0.3	34.6 ± 3.1	8.6 ± 0.1	36.8 ± 1.6	7.7 ± 1.0
8	77.4 ± 1.8	-	65.4 ± 1.1	49.7 ± 3.0	47.3 ± 6.2	36.8 ± 0.9
9	14.4	18.0±0.5	11.2 ± 0.7	11.9± 1.0	11.2 ± 0.6	12.4 ± 0.1
10	9.2 ± 0.4	14.7± 1.1	5.5 ± 0.3	8.7 ± 0.2	5.2 ± 1.6	5.2 ± 0.2
11	8.4 ± 0.1	2.6 ± 0.4	5.0 ± 0.1	4.0 ± 0.1	3.1 ± 0.3	5.5 ± 0.1
Cisplatin	6.4 ± 0.6	10.8±0.8	1.6 ± 0.3	21.8 ± 6.9	11.6 ± 2.2	12.3 ± 0.7

Example 6.3: Induction of Apoptosis by the Au(III)-NHC Complexes through inhibition of TrxR activity

[00306] Example 3 describes the result of studies showing that complex **9** would induce apoptosis in HeLa cancer cells through inhibition of TrxR activity.

[00307] Thioredoxin reductase (TrxR) plays the central role in the thioredoxin system; as a result, large amounts of research have focused on the inhibition of TrxR activity to treat cancer. Although a number of compounds were reported to inhibit purified TrxR, only a few reports showed they can inhibit cell-based TrxR activity.

[00308] Electrospray ionization-mass spectrometry (ESI-MS) analysis and ¹H NMR experiment shows that the Au(III)-NHC complexes can quantitatively react

with GSH with 1:3 molar ratio; two equivalent of GSH was oxidized to form GSSG and the remaining one equivalent of GSH was bound to Au(I) (see details in Fig. 3). As Au(I)-NHC complexes are well-known thioredoxin reductase (TrxR) inhibitor, thus they may inhibit the cellular TrxR activity.

[00309] Cell-based TrxR activity experiment was incorporated in our experiments. Complex **1**, **2**, **9** and auranofin were added to HeLa cells and incubated for 1 h, and then the cells were extracted with ice-cold lysis buffer (50 mM phosphate buffer, pH 7.4, 1 mM EDTA, 0.1% Triton-X 100). The cell lysates (10 µg proteins) were added to a buffer (100 µL) containing 100 mM potassium phosphate, pH 7.4, 1 mM EDTA and 0.2 mM NADPH. Reaction was initiated by adding 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB, 3 mM final) and the TrxR activities were determined as increases in O.D.410 nm in 10 min. It was found that complex **1**, **2** and **9** can inhibit cell-based TrxR activity similarly to auranofin (Fig.4a).

[00310] Meanwhile, considerable attention has been paid on apoptosis for which can lead cancer cell death. After treating HeLa cells with 15 µM of complex **9** for 48 h, apoptosis related PARP, caspase 3, 7 and 9 were activated according to western blotting results (Fig. 4b).

[00311] Thus the Au(III)-NHC complexes can induce apoptosis of cancer cells, probably caused by the inhibition of TrxR activity (Fig. 4c).

Example 6.4: *In vivo* Anti-Cancer Property of the Au(III)-NHC Complexes

[00312] Example 4 describes the *in vivo* tumor inhibition effects of mice bearing HeLa xenograft by complex **5**.

[00313] Female BALB/cAnN-nu (Nude), 5-7 weeks old, were purchased from the Charles River Laboratories (Wilmington, MA) and cared for according to the guidelines of the Laboratory Animal Unit of the University of Hong Kong (HKU). All animal experiments were conducted under the guidelines approved by the Committee

on the Use of Live Animals in Teaching and Research of HKU. To establish the HeLa xenograft model, 4×10^6 HeLa cells suspended in 100 μ l of PBS were inoculated into the back flanks of female BALB/cAnN-nu (Nude) mice by subcutaneous injection. When the tumor volumes reached about 50 mm³ (4 days after tumor inoculation), the mice were randomly divided into different treatment groups (3 mg/kg of **5** or solvent control). Complex **5** was reconstituted in PET diluent (60% polyethylene glycol 400, 30% ethanol, 10% Tween 80). Complex **5** dissolved in PET diluent and then diluted in PBS or PBS supplemented with equal amount of PET were injected into the mice by intratumoral injection once every three days until the mice were sacrificed. In this model, the volume of PET diluent injected into each mouse was $\leq 6 \mu$ l. Tumor sizes were measured once every 3 times a week, and tumor volume (V) was calculated by the formula $V = ab^2 \times 0.52$, where a and b were the longest and the shortest diameters of the xenografted tumor. The tumor inhibition was calculated according to the following formula:

$$\text{[00314]} \quad \text{Inhibition percentage} = [1 - (V - V_0)/(V' - V_0')] \times 100 \%$$

where V and V' are the tumor volumes of **5** treatment and solvent control, respectively. V_0 and V_0' are the initial tumor volumes of the **5** treatment and solvent control, respectively.

[00315] Results shows that after the treatment by 3 mg/kg of **5**, significant reduction in tumor volume was found after 11 ($p < 0.05$) and 14 ($p < 0.01$) days, with tumor inhibition up to 60 % and 76 %, respectively (Fig. 5a, c d). No mouse death or mouse body weight loss was found (Fig. 5b). The slight increase of body weight of mice in the solvent control group might be due to faster growth of the tumors in this group of nude mice.

[00316] Preliminary toxicity experiment demonstrated that 20 mg/kg of **5** was toxic to mice while 7 mg/kg caused slight drop of body weight, thus the effective dosage (3 mg/kg) is quite lower than the lethal dosage.

[00317] The dosage of the Au(III)-NHC complex is a sufficient amount to inhibit tumor growth and may be dependent on the type of cancer and location of the cancer. This amount may be about 0.1 mg/kg to about 50 mg/kg for mice and humans. Direct intratumoral injection of the Au(III)-NHC complex is preferred. Many pharmaceutical dosage forms are available for administering the Au(III)-NHC complexes. Preferably, pharmaceutical dosage forms suitable for injection or infusion include sterile aqueous solutions or dispersions or sterile powders comprising the Au(III)-NHC complexes which are adapted for facile preparation of sterile injectable or infusible solutions or dispersions are utilized. In all cases, the dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol, vegetable oil, nontoxic glyceryl esters and suitable mixtures thereof.

[00318] What is describe herein is merely illustrative of the Au(III)-NHC complex and their activity. Other embodiments may be implemented by those skilled in the art without departing from the scope and spirit of the present invention.

Example 6.5: Application as Thiol Probe Depending on Fluorescence Changes

[00319] Example 5 describes the result of fluorescence changes of **9** towards different analysts and the application for cellular thiol detection and cell imaging.

[00320] ESI-MS analysis and ¹H NMR experiment shows that the Au(III)-NHC complex can quantitatively react with GSH with 1:3 molar ratio, where the N[^]N[^]N ligand was released with the formation of GS-Au(I)-NHC compound. As the free N[^]N[^]N ligands are highly emissive, thus they may serve as fluorescent switch on probe for thiol detection. Compound **9** was used as an example to detect fluorescence changes towards different analysts and the application as cellular imaging agents.

[00321] Fluorescent response towards different Analysts by **9**: NaCl, KCl, MgCl₂, CaCl₂, the amino acids (Ser, Pro, Leu, Ile, His, Ala, Cys), DTT and GSH stock solutions were freshly prepared in 1×PBS : DMSO = 9:1 (2 mM). **9** was dissolved in DMSO at room temperature to afford the probe stock solution (10 mM). Then 10 μL of **9** was added to 5 mL of different analyte solutions. The resulting solution was shaken well. After 2 min, the emission spectra were recorded. After 2 h and 12 h, emission intensity has no significant change. For all the measurement, the excitation wavelength was 340 nm and the excitation and emission slit widths were 3 nm. The emission intensity obtained after reacting **9** with each analyte in the aforementioned conditions was measured and compared.

[00322] Fluorescence microscopic examination **9**: HeLa cells (1×10^5 cells) were seeded in a one chamber slide (Nalgene; Nunc) with culture medium (2 mLwell⁻¹) and incubated at 37 °C in a humidified atmosphere of 5% CO₂/95% air for 24 h. After treating with **9** (20 μM, 1 mL) for 10 min, cells were directly exposed for fluorescent imaging without removing the old medium. The bright-field and fluorescent images (ex: 340 nm) were examined in Axiovert 200 (Carl Zeiss) and in an Axio Vision Rel. 4.5 imaging system (Carl Zeiss).

[00323] It was found that release of the H₂BPB ligand upon treatment of **9** with GSH or Cys led to at least 200-fold increase in emission intensity (Fig. 6). No fluorescence was found when **9** was treated with Na⁺, K⁺, Ca²⁺, Mg²⁺, or thiol-free amino acids such as Ala, Ser, Pro, Leu, Ile and His. Complex **9** is sensitive to thiol-containing compounds including GSH, Cys and the commonly used disulfide bond reducing agent dithiothreitol (DTT).

[00324] For fluorescence microscopy analysis, it was found that after only 10 min, significant blue fluorescence was detected in cytoplasm but not in nucleus or extracellular environment (Fig. 6), suggestive of the stability of **9** towards cell culture media and efficient activation of Au(III)-NHC complex to Au(I)-NHC in cytoplasm and deliver the active Au(I)-NHC to its molecular target, TrxR.

[00325] The invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

[00326] All references cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.


[00327] Reference:

[Berners-Price, S. J. et al. *J. Am. Chem. Soc.* 2008, 130, 12570-12571.]

Claims

What is claimed is:

1. The composition of the Au(III)-NHC complexes for cancer treatment or for fluorescent thiol detection, with an effective amount of the Au(III)-NHC complexes, have a formula **I**, wherein,



I

- R₁, R₂, R₇, R₈, are each independently selected from the group -H, and R₃, R₄, R₁₀, R₁₁ are each dependently selected from an electron pair or -H; or each pair of R₁ and R₃, R₂ and R₄, R₇ and R₈, R₁ and R₁₀, R₂ and R₁₁ is independently joined together to form



;

- R₅, R₆, R₉, are each independently selected from a -H, -CH₃, -C₄H₉, -C₆H₁₃, -C₈H₁₇, -C₁₀H₂₁, -C₁₆H₃₃, -C₃H₆PPh₃⁺;
- n is an integer ranging from +1 to +2;
- y is equal to the absolute value of n/b; and
- X is selected from a carbon or a nitrogen atom;
- Y is selected from a carbon or a nitrogen atom;

2. The composition of claim **1**, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;
- R₁₀, R₁₁ are each lone electron pairs;

- R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;
- R₅, R₆ are each -CH₃;
- n is +1, and
- yA^b is CF₃SO₃⁻.

3. The composition of claim 1, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;
- R₁₀, R₁₁ are each lone electron pairs;
- R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;
- R₅ is -CH₃;
- R₆ is -C₄H₉;
- n is +1, and
- yA^b is CF₃SO₃⁻.

4. The composition of claim 1, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;
- R₁₀, R₁₁ are each lone electron pairs;
- R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;
- R₅ is -CH₃;
- R₆ is -C₈H₁₇;
- n is +1, and
- yA^b is CF₃SO₃⁻.

5. The composition of claim 1, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;

- R₁₀, R₁₁ are each lone electron pairs;
- R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;
- R₅ is -CH₃;
- R₆ is -C₁₀H₂₁,
- n is +1, and
- yA^b is CF₃SO₃⁻.

6. The composition of claim 1, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;
- R₁₀, R₁₁ are each lone electron pairs;
- R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;
- R₅ is -CH₃;
- R₆ is -C₁₆H₃₃;
- n is +1, and
- yA^b is CF₃SO₃⁻.

7. The composition of claim 1, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;
- R₁₀, R₁₁ are each lone electron pairs;
- R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;
- R₅, R₆ are each -C₄H₉;
- n is +1, and
- yA^b is CF₃SO₃⁻.

8. The composition of claim 1, wherein,

- X is a nitrogen atom;

- Y is a carbon atom;
- R₁₀, R₁₁ are each lone electron pairs;
- R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;
- R₅, R₆ are each -C₆H₁₃;
- n is +1, and
- yA^b is CF₃SO₃⁻.

-

9. The composition of claim 1, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;
- R₁₀, R₁₁ are each lone electron pairs;
- R₁, R₂, R₃, R₄, R₇, R₈, R₉ are each -H;
- R₅ is -CH₃;
- R₆ is -C₃H₆PPh₃⁺;
- n is +2, and
- yA^b is 2CF₃SO₃⁻.

10. The composition of claim 1, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;
- Each pair of R₁ and R₃, and R₂ and R₄ is joined together to form



- R₇, R₈, R₉ are each -H;
- R₁₀, R₁₁ are each lone electron pairs;
- R₅, R₆ are each -CH₃;
- n is +1, and
- yA^b is CF₃SO₃⁻.

11. The composition of claim 1, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;
- Each pair of R₁ and R₃, and R₂ and R₄ is joined together to form



- R₇, R₈, R₉ are each -H;
- R₁₀, R₁₁ are each lone electron pairs;
- R₅, R₆ are each -C₄H₉;
- n is +1, and
- yA^b is CF₃SO₃⁻.

12. The composition of claim 1, wherein,

- X is a nitrogen atom;
- Y is a carbon atom;
- Each pair of R₁ and R₃, and R₂ and R₄ is joined together to form



- R₇, R₈, R₉ are each -H;
- R₁₀, R₁₁ are each lone electron pairs;
- R₅, R₆ are each -C₆H₁₃;
- n is +1, and
- yA^b is CF₃SO₃⁻.

13. The composition of claim 1, wherein,

- X is a carbon atom;
- Y is a nitrogen atom;
- R₃, R₄ are each lone electron pairs;

- R₁, R₂, R₇, R₈, R₉, R₁₀, R₁₁ are each -H;
- R₅, R₆ are each -CH₃;
- n is +1, and
- yA^b is OSO₂CF₃⁻.

14. The composition of claim 1, wherein,

- X is a carbon atom;
- Y is a nitrogen atom;
- R₃, R₄ are each lone electron pairs;
- R₁, R₂, R₇, R₈, R₉, R₁₀, R₁₁ are each -H;
- R₅ is -CH₃;
- R₆ is -C₄H₉;
- n is +1, and
- yA^b is CF₃SO₃⁻.

15. The composition of claim 1, wherein,

- X is a carbon atom;
- Y is a nitrogen atom;
- R₃, R₄ are each lone electron pairs;
- R₁, R₂, R₇, R₈, R₉, R₁₀, R₁₁ are each -H;
- R₅ is -CH₃;
- R₆ is -C₁₆H₃₃;
- n is +1, and
- yA^b is CF₃SO₃⁻.

16. The composition of claim 1, wherein,

- X is a carbon atom;
- Y is a nitrogen atom;

- R₃, R₄ are each lone electron pairs;
- R₁, R₂, R₉, R₁₀, R₁₁ are each -H;
- R₇ and R₈ are joined together to form



-
- R₅, R₆ are each -CH₃;
- n is +1, and
- yA^b is CF₃SO₃⁻.

17. A method of synthesis of the Au(III)-NHC complex of claim 1, comprising two steps: i) reacting H₂N[^]N[^]N ligand with KAuCl₄ to form N[^]N[^]N-Au-Cl, and ii) reacting of N[^]N[^]N-Au-Cl with silver triflate (AgOTf) and silver carbene (X-Ag-NHC, X = Cl, Br, or I) to form the Au(III)-NHC complex of claim 1.

18. A method of claim 17, wherein H₂N[^]N[^]N comprise one or more of 2,6-bis(1*H*-benzo[*d*]imidazol-2-yl)pyridine (H₂BPB), 2,6-di(1*H*-imidazol-2-yl)pyridine (H₂IPI), or 2,6-di(1*H*-pyrazol-5-yl)pyridine (H₂PPP)

19. A method claim 17, wherein N[^]N[^]N comprise one or more of deprotonated 2,6-bis(1*H*-benzo[*d*]imidazol-2-yl)pyridine (BPB), 2,6-di(1*H*-imidazol-2-yl)pyridine (IPI), or 2,6-di(1*H*-pyrazol-5-yl)pyridine (PPP).

20. A method of claim 1, wherein the Au(III)-NHC complex comprises a gold(III) atom coordinated to a di-anionic substituted 2,6-bis(1*H*-benzo[*d*]imidazol-2-yl)pyridine, 2,6-di(1*H*-imidazol-2-yl)pyridine, or 2,6-di(1*H*-pyrazol-5-yl)pyridine ligand and a N-heterocyclic carbene ligand.

- 21.** A method of “cancer treatment” of claim **1**, wherein the cancer is one or more of hepatocellular carcinoma, cervical epithelioid carcinoma, lung carcinoma, breast cancer, melanoma and nasopharyngeal carcinoma.
- 22.** A method of “cancer treatment” of claim **1**, wherein treatment means induction of cell death, or inhibition of cellular proliferation, or inhibition/poisoning of thioredoxin reductase, or inhibition of tumor growth *in vivo*.
- 23.** A method of “fluorescent thiol detection” of claim **1**, wherein thiol means thiol-containing compounds. Non-limiting examples of such compounds include cysteine, glutathione and dithiothreitol
- 24.** The method of claim **1** wherein the preferred amount of the administration of formula **I** is about 0.1 mg/kg to 50 mg/kg for cancer treatment and 1 μM –500 μM for thiol detection.

FIG. 1 (A)




FIG. 1(B)







FIG. 2

(A)



(B)






FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A





FIG. 4B



5

FIG. 4C






FIG. 5




5

FIG. 6


(A)



(B)



(C)



INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2013/001397

A. CLASSIFICATION OF SUBJECT MATTER		
See extra sheet		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC: C07F 1, A61K 31, A61P 35, G01N 21, G01N 37		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CNKI, CNPAT, WPI, EPODOC, CAPLUS, REG (STN)		
Au, aurum, gold, auric, aurous, N-heterocyclic carbene, imidazol, complex, ligand, cancer, tumor, thiol, probe, fluorescent, luminescent, search according to the structure of the complex I in claim 1		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	Zou, Taotao et al., Gold(III) Complexes Containing N-Heterocyclic Carbene Ligands: Thiol "Switch-on" Fluorescent Probes and Anti-Cancer Agents, <i>Angewandte Chemie, International Edition</i> , 01 February 2013, Vol.52, No.10, pages 2930-2933, see the whole document, especially figure 1	1-24
PX	CISNETTI, FEDERICO et al., Metal/N-Heterocyclic Carbene Complexes: Opportunities for the Development of Anticancer Metallodrugs, <i>Angewandte Chemie, International Edition</i> , 02 October 2013, Vol.52, No.46, pages 11976-11978, see the whole document, especially compound 3 in page 11976	1-24
A	US 7572912 B2 (UNIV HONG KONG) 11 August 2009 (11.08.2009) see the whole document, especially claims 1-18 and example 1	1-24
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 05 Feb. 2014 (05.02.2014)	Date of mailing of the international search report 20 Feb. 2014 (20.02.2014)	
Name and mailing address of the ISA/CN The State Intellectual Property Office, the P.R.China 6 Xitucheng Rd., Jimen Bridge, Haidian District, Beijing, China 100088 Facsimile No. 86-10-62019451	Authorized officer CHANG, Xiaoyu Telephone No. (86-10)62084403	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2013/001397

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1, 21-22
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 1 relates to the composition for cancer treatment, and claims 21-22 relate to the method of cancer treatment. They all belong to the treatment of diseases, which do not comply with the requirement of rule 39. This international search report is established on the basis of subject-matters anticipated reasonably, i.e., "Claim 1, The composition of Au(III)-NHC complexes for preparing the medicament for cancer treatment or....."; "Claim 21, The use of the composition in claim 1 for preparing the medicament for cancer treatment, wherein". And the subject-matter of claim 22 is the same as that of claim 21.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CN2013/001397

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
US 7572912 B2	11.08.2009	US 2006091378 A1	04.05.2006
		WO 2006045235 A1	04.05.2006
		CN 101098946 A	02.01.2008
		CN 101098946 B	05.12.2012

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2013/001397

A. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC) or to both national classification and IPC:

C07F 1/12 (2006.01) i

A61K 31/28 (2006.01) i

A61P 35/00 (2006.01) i

G01N 31/22 (2006.01) i

G01N 21/77 (2006.01) i